Skip to main content




EU could give final approval for Pfizer COVID-19 vaccine on Dec 23

EU could give final approval for Pfizer COVID-19 vaccine on Dec 23

FILE PHOTO: A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in front of displayed Pfizer logo in this illustration. (REUTERS/Dado Ruvic)

BRUSSELS: The European Union could give final approval for the Pfizer-BioNTech COVID-19 vaccine as early as Dec 23, a senior Commission official said on Wednesday (Dec 16), only two days after a possible green light from the bloc's regulator.

Under EU rules, the European Medicines Agency (EMA) recommends the approval of new medicines and vaccines, but the final decision to allow them onto the market is made by the EU executive Commission after consultation with EU governments.

The EMA said on Tuesday it could issue a recommendation on the Pfizer-BioNTech vaccine on Dec 21.

"If this is the case, the European Commission is ready to provide the formal authorisation placing it in the market in supersonic, fast procedures," Commission vice-president Margaritis Schinas told EU lawmakers.

READ: Nurse gets New York's first COVID-19 vaccine as US rollout begins

"We can do it in two days," he said, meaning final approval could come as early as Dec 23.

This further shortens the approval timetable after the EMA brought forward by more than a week its possible decision, originally planned for Dec 9. The Commission said last week it could approve vaccines within three days of approval by the EMA.

Britain and the United States are among countries which have already approved the Pfizer-BioNTech vaccine.

The EMA usually takes at least seven months to issue a recommendation on vaccines after it receives full data from manufacturers, while the Commission can take as long as two months to authorise a vaccine after EMA approval.

If the EMA approves the vaccine on Monday, it will have taken just 20 days to assess the shot since it received data from large-clinical trials from Pfizer on Dec 1.

READ: Pressure mounts on EU drug regulator to approve Pfizer COVID-19 vaccine

The approval would be a conditional authorisation, meaning the vaccine would continue to be strictly monitored for efficacy and possible side-effects.

Available data show that in the short term the vaccine is highly effective against the new coronavirus and causes only mild side-effects. But long-term data are not yet available.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak:​​​​​​

Source: Reuters/lk


Also worth reading